3 verified stories covering Drug R&D, product updates and industry developments.
OpenAI and Novo Nordisk announced a strategic partnership on April 14 to integrate AI across the drugmaker's entire value chain, from molecular screening to clinical data analysis and global sales operations, with full integration targeted by year-end.
Eli Lilly has signed a $2.75 billion agreement with Insilico Medicine to license a portfolio of AI-designed oral small-molecule drug candidates, marking a shift from using AI as a tool to purchasing AI-generated drugs themselves.
Eli Lilly has launched LillyPod, an in-house AI supercomputing cluster built with 1,016 NVIDIA Blackwell Ultra GPUs, and announced a joint $1 billion AI co-innovation lab with NVIDIA in San Francisco.